(-)-Epigallocatechin-3-gallateはヒト大腸癌肝転移を抑制する by 丸山 岳人
(-)-Epigallocatechin-3-gallate suppresses
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8ɝDVEr*£Ȱ$ 8 ƾɐðßɜǖǳ(*|( (-)-epicatechin 
( EC )ɜ(-)-epicatechin-3-gallate ( ECG )ɜ(-)-epigallocatechin ( EGC )ɜ
(-)-epigallocatechin-3-gallate ( EGCG ) Ð/9#






8%$ĮǪƦºř;Ʃĸ8%4 14ɜc-Jun N-terminal kinase ( JNK ) 
4 p38 '&)MXpMĜǆ mitogen-activated protein kinase ( MAPK ) ;
ŹĞ½ɜ=eXsKM;ĎȖ%åÒ9#













ǃ 2 ǂ Ʈƫ  
 
 œƵǀ$*ɜin vitro $_XíǫƨǏǤŝ(û8 EGCG )éūĬ²ºř)
Šȅ(¹ɜ_XíǫƨǏǤŝ;ƛ
f@MǡșƻjWo;Ǽɜǡșƻ
(û8 EGCG )ĮǪƦºř;ň6(8%;Ʈƫ%ɝ 
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ǃ 3 ǂ óɖńŵ  
 
3-1. EGCG 
 EGCG * Sigma-Aldrich ( St.Louis, MO, USA ) 57Ȕ¢ɝǏǤ(ƀ¹
82(ɜEGCG  1 mg / ml ('85(ǵơŰ(ƆȂɜ-20 $




 _XíǫƨǏǤŝ%# RKO 5+ HCT116 ;ƛ
ɝDulbecco’s 
modified Eagle’s medium ( D-MEM; Wako Pure Chemical Industries, Osaka, 
Japan ) ( 10 % fetal bovine serum ( FBS; Hyclone, Logan, UT, USA ) 5
+ 1 % penicillin and streptomycin ( Invitrogen, Grand Island, NY, USA ) ;







;Ƅò8 WST-8 Ȋɖɜ5+ɜǏǤéūƕ(ȿ#* deoxyribonucleic 
acid ( DNA ) Îĥ)ıŤ$	8 5-bromo-2’-deoxyuridine ( BrdU ) È7Ȝ0Ȋ
ɖ;Ņǹɝ´ Ǟ*ɜCell Counting Kit-8 ( Dojindo Laboratories, Kumamoto, 
 5 
Japan ) ;ƛ
ɜĕǞ*ɜCell Proliferation ELISAɜBrdU colorimetric ( Roche 
Diagnostics, Penzberg, Germany ) ;ƛ
#Šȅɝ¥ƫ(*ɜíǫƨǏ
Ǥŝ; 96 well bpsX( 3  103  / well!ĻƾɜtŌãɔĕ( 




XsKMȧƽ$ƚ8łƎ½ DNA ; TdT-mediated dUTP nick end 
labeling ( TUNEL ) ŵ(57Š¬8 DeadEndTM Colorimetric TUNEL 
System ( Promega, Madison, WI, USA ) ;ƛ
#Šȅɝ¥ƫ(*ɜíǫ
ƨǏǤŝ; Lab-Tek II Chamber Slide ( Nalge Nunc International, Tokyo, 







3-5. Western blot 
 íǫƨǏǤŝ; 6 cm dish ( 3  105 !Ļƾɜ48 ŋȾãɔĕ
( EGCG ;ƀ¹ɜ12 ŋȾĕ)ǏǤ6Rr^Fȓ;ĵÈɝǏǤƆȂŽ
; 10 % sodium dodecyl sulfate-polyacrylamide gel $ɈůŸ»ĕ(ɜ
nitrocellulose membrane ( Millipore, Bedford, MA, USA ) (ș¨ɝtŦĮ
*ɜƚðéūȿȣKGZo%# phospho-Akt ( Ser473 )ɜAktɜMXpMĜ
ǆKGZo%# phospho-p38ɜp38ɜ¦ßĞIrXqso%# β-actin ;
 6 
ƛ
ɝŦĮ*ɜanti-rabbit IgG horseradish peroxidase-conjugated 
antibody ;ƛ




3-6. RNA )į¬ 
 íǫƨǏǤŝ; 6 cm dish ( 3  105 !Ļƾɜ48 ŋȾãɔĕ
( EGCG ;ƀ¹ɜ2 ŋȾĕ)ǏǤ6 ribonucleic acid ( RNA ) ;ĵÈ




 RNA )FCnV>s%Ɖċ; NanoDrop Spectrophotometer ( NanoDrop 
Technologies, Wilmington, DE, USA ) ;ƛ
#ȉɜ-#) RNA Š
) 260 / 280 nm )Ñ ċŭ 2.0 u$	8%;ƶȌɝ 
 Ƞș¨ȳǌ(58 complimentary DNA )Îĥ*ɜAMV Reverse 
Transcriptase ( Promega, Madison, WI, USA ) % random primers ( Takara 
Bio Inc., Shiga, Japan ) ;ƛ
#Ņǹɝ¥ƫ(*ɜ1 mM dNTPs 
( Fermentas Life Sciences, Burlingame, ON, Canada )ɜrandom primers 0.025 
µg / mLɜAMV Reverse Transcriptase 0.25 U / mLɜį¬ RNA 500 ng ;5
ſÔɜPCR system 9700 ( Applied Biosystems, Foster, CA, USA ) ;ƛ

# 30  $ 10 ­Ⱦɜ37  $ 60 ­Ⱦɜ95 $ 5 ­Ⱦɜ4  $©Ã%

bqXIso$ǹ
ɜcomplimentary DNA * -80  $ðɝ 
 
3-7. n=oR?h RT-PCT 
 7 
 œóɖ$*ɜvascular endothelial growth factor receptor 2 ( VEGFR2 )ɜ
epidermal growth factor receptor ( EGFR )ɜhuman EGFR-related 2 ( HER2 ) 
5+ c-Met ) 4 !)TqKrEZsOâÉ÷)ƩƗ;Šȅɝ/ɜ
¦ßĞIrXqso%# Glyceraldehyde-3-phosphate dehydrogenase 
( GAPDH ) ;ƛ
ɝmRNA )ȱ¯* GenBank ) web J?X$ŠǍɝ
bm?fs)ȇȄ*ɜPrimer Express® software for Real-Time PCR ver. 3.0 
( Applied Biosystems, Foster City, CA, USA ) ;ƛ
#ǹ
ɜȇȄbm?
fs* Hokkaido System Science ( Hokkaido, Japan ) 57Ȕ¢ ( ǻ 1 ). 
 n=oR?h reverse transcription polymerase chain reaction ( RT-PCR ) 
*ɜSYBR Green Realtime PCR Master Mix-Plus ( Toyobo, Osaka, Japan ) %
7300 Real-time PCR system ( Applied Biosystems ) ;ƛ
#ɜǼȢšǞ)Ƹ
Ťƅƫ'ĨɌ(Ė
óɖ;ŅǹɝJsfoJ?Fms)ȇò*ɜ95  $ 








 -#)»Əóɖ$ɜ8 Ȥə$ȶ 21  26 g )ɇĞ severe combined 







microclip ( Aesculap, Tuttlingen, Germany ) $Fmrbɜ1 ­Ⱦ)£ǡǷǸ
;ɝFmrb;ȂɃ 1 ­Ⱦ)§Ɗźĕ(ɜǨvŢ( 27 HsLȸ$ 2  
106 ) RKO ǏǤ;ŷüɝǨǪƦ6)Ǭǩ¦Ļƾ;ɀ82ɜǨ
Ǯ;ĺ¬ɜǬȰ;ȼ¸ɜĨǺ;ǐ~ɝ 
 f@M*ŒŲƧ) control Ǜ ( n = 12 ) % EGCG ;ĭx EGCG Ǜ 
( n = 12 ) (­ɝEGCG Ǜ$*ƨǏǤƻşĕ 7 ŇƮ6 2 ȤȾ(: 




 ǡșƻɊƿ;ȉ82(ɜĺ¬ǡǮ) 4 Ǵ;99 2 !(­·
ɜ10 ɚ neutral buffered formaldehyde$Ýòɝ^m`>r¼Ƙɜ
99)Ťœ$Ŏí·Ɋ('85( 4 µm (®7¬ɜhematoxylin-eosin
Śǲ;ǹ ɝǡșƻɊƿ*ė69 8 ®Ǝ;ȁúɜŨăǡǮ(û8șƻ







o$§ŰÔɜ¦ÚĞdoCEKSsOŹĞ;aqUF82( 0.03 % 
hydrogen peroxidase(Żɝ]UFGm@rYŚǲ;Ƃ82( 3 % 
bovine serum albumin ( BSA ) $´«Ƙĕ(ɜtŦĮ%# anti-CD31 
antibody ( Lifespan Bioscience, Seattle, WA, USA ) ; 3 % BSA $ 100 (
Ăȵ# 1 ŋȾõƃ$«ƘɝŦĮ%# peroxidase-labeled polymer 
conjugated to goat anti-rabbit immunoglobulins ( Dako Japan, Tokyo, 
Japan ) ; 30 ­Ⱦõƃ$«ƘɜƩǲ* diaminobenzidine chromogen 
( Dako Japan ) ;ƛ
ɝHematoxylin $ûŭŚǲĕ(ɜBR\so$ǧ





*ɜ1,200 g $ 10 ­ȾȫĚĕ(uƁ;ÙÇɝFUJI DRI-CHEM 7000 
( Fuji Film, Tokyo, Japan ) ;ƛ
#ɜamino aspartate aminotransferase 
( AST ) % alanine aminotransferase ( ALT ) ;Ƅòɝ 
 
3-13. ǕȄñƫȂŘ 
 -#)ƄòǓř;ąá ± Ťƅā$ǻȆɝ2 ǛȾ)Šȅ$* 
 10 
unpaired t-testɜ3 ǛȾu)Šȅ$*ɜone-way analysis of variance with the 
Bonferroni post-hoc-test ;ƛ
ɝ-#)óɖ(




ǃ 4 ǂ Ǔř  
 
4-1. EGCG (58éūĬ²ºř 
 EGCG íǫƨǏǤŝ)éū(x8Ēɋ;ŠȅɝíǫƨǏǤŝ( 
EGCG ;ƀ¹ 24 ŋȾĕ(ɜǏǤƚðƕ; CCK-8 ( Ü 1A, B ) $ɜǏǤé
ūƕ; BrdU ( Ü 2A, B ) $ȉɝzíǫƨǏǤŝ*%3(ɜEGCG 50 
µM % 100 µM $ŏġ(ǏǤƚðƕ%ǏǤéūƕvɝ 
 
4-2. EGCG (58=eXsKMȍýºř 
 EGCG (58íǫƨǏǤŝ)=eXsKMȍýºř;ƶȌ82(ɜ 
EGCG ƀ¹ 4 ŋȾĕ( TUNEL Śǲ$ȉ ( Ü 3, 4 )ɝzíǫƨǏǤ
ŝ*%3(ɜEGCG 0 µM % 25 µM $*=eXsKMǏǤ;Ȍ2' ɜ
EGCG 50 µM % 100 µM $*=eXsKMǏǤ)¬Ɨ;Ȍ2ɝ 
 
4-3. EGCG KGZoȩ(x8Ēɋ 
 EGCG íǫƨǏǤŝ)KGZoȩ(x8Ēɋ;Šȅ82(ɜţ
'Ɖċ) EGCG ;ƀ¹ 12 ŋȾĕ(Jrbo;ĵÈɜWestern blot $Š
ȅɝzíǫƨǏǤŝ$ɜEGCG 25 µMɜ50 µM 5+ 100 µM $ Akt )
ǧnrȴ½;Ȍ2 ( Ü 5 )ɝRKO $* EGCG 50 µM % 100 µM $ p38 
)nrȴ½;Ȍ2ɜHCT116$* EGCG 100 µM $ p38 )nrȴ½;Ȍ2 
( Ü 5 )ɝ 
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4-4. EGCG TqKrEZsOâÉ÷(x8Ēɋ 
 EGCG TqKrEZsOâÉ÷(x8Ēɋ;Šȅ82(ɜ 
EGCG ;ƀ¹ 2 ŋȾĕ(Jrbo;ĵÈɜn=oR?h RT-PCR $Šȅ
ɝŠȅTqKrEZsOâÉ÷*ɜVEGFR2ɜEGFRɜHER2 5
+ c-Met ) 4 ƾɐ$	8ɝEGFRɜHER2 5+ c-Met $* EGCG ;ƀ
¹#3 mRNA )ƩƗ(ê½*Ȍ2' ɜVEGFR2 $* EGCG 25 
µMɜ50 µM 5+ 100 µM $ŏġ'ƩƗv;Ȍ2 ( Ü 6 )ɝ 
 
4-5. EGCG )ǡșƻǪƦ(û8ºř 
 EGCG _XíǫƨǏǤŝ)ǡșƻǪƦ(x8Ēɋ;Šȅ82(ɜ 
RKO (58ǡșƻjWo;Ǽɝcontrol Ǜ$*ŒŲƧ%ɜEGCG Ǜ
$*ƨǏǤƻş 1 ȤȾĕ6 2 ȤȾ(:7 1 ŇŬ(Ȅ 7 Ù EGCG 30 
mg / kg body weight ;Ǭǩ¦ĭxɝÜ 7A *zǛ)ǠƲɜÜ 7B * 
hematoxylin-eosin Śǲ(58ƤƘǑǘ$	8ɜEGCG Ǜ$ǡșƻǪƦ)
éí)Ĭ²Ǿ69ɝÜ 8 *zǛ$)ǡșƻɊƿ;ŭȚ3)$ɜEGCG 
Ǜ$ŏġ(ǡșƻɊƿ)Ƃÿ;Ȍ2ɝǡșƻǪƦ¦) TUNEL Śǲ$* 
EGCG Ǜ$=eXsKMǏǤìǾ69 ( Ü 9A )ɝ6(ɜEGCG (5
8ǪƦ¦)ǸǈŃƚ(x8Ēɋ;Ȏ-82 anti-CD31 antibody $Ǹǈ¦
ƭǏǤ;¡ƣŚǲ8%ɜEGCG Ǜ$ŃƚǸǈ)Ƃÿ;Ȍ2 ( Ü 9B )ɝ 
 
4-6. EGCG f@M(Å.¶ƛ 
 EGCG f@M(Å.¶ƛ%#ɜȶê½ɜ5+ɜǡťǥɆö;Š
 13 
ȅɝzǛȾ$ȶê½(ŏġā*Ȍ2'  ( Ü 10A )ɝ/ɜǸƁ ASTɜ











































































 p38 * extracellular signal-regulated kinase ( ERK ) 4 JNK %%3( 
MAPK `<gns;đĥ#7ɜ)tǛ)EZsO*ɜéūɜ­½ɜ=e
XsKM'&$ȶǽ'ē·;İ #
8 26ɝƑ(ɜp38 % JNK *ɜɗŻȡÞɜ
ƋƥĞJ?XD?rɜȴ½ɜƍKlUFɜǎëǗ'&)ǏǤë6)³ƈ(5
 #ŹĞ½8%6MXpMĜǆ MAPK %#ƴ69#
8 27ɝǏǤë
MXpM(5 # p38 ŹĞ½8%ɜţ'äȓưƛɜƋƥÆĜɜ
ǏǤ­½ɜǏǤÓőŧɜǜ½ɜ=eXsKM'&;ĎȖ%ƴ69
#
8 28ɝIrinotecan 4 oxaliplatin '&) DNA ;RsHUX(#
8Į
ƨµ p38 ;#=eXsKM;ĎȖ%åÒ9#7 29,30ɜ 
EGCG (
#3 p38 4 JNK ;#=eXsKMȍý98%å
Ò9#
8 15ɝÙ)Ħ) in vitro )Šȅ$3ɜEGCG ĭx(5 # p38 
ŹĞ½#7ɜ9(5 #=eXsKMȍý9%ǝ698ɝ 
 
 ȝĆɜǖǳĥ­;Ð1JbnirX)Őƛ$ǡɆö;ĎȖƥ4 31ɜ 
in vivo $ EGCG )ìȷĭx(57ǡɆöĠȖ9%
åÒ	7 32ɜ 
EGCG ǡǮ(x8ĒɋĤĝ9#
8ɝIn vivo $ǡɆö;ĠȖ 
EGCG ĭxȷ*ɜǬǩ¦ĭx$* 100 mg / kg / dayɜǒËĭx$* 500  
 17 
1,500 mg / kg / day $	7 32-34ɜĦÙƛ EGCG ĭxȷ%ŭȚ
#'7ìȷ$	8ɝ/ɜEGCG *Ũă_XǡǏǤ%ŭȚ#ɜ_XǡǏǤ
ƨ(û#57Đéū;Ɂö8%åÒ9#





 ȝĆ)íǫƨ)½ñƧŵ)|ź*ìµƛ½ñƧŵ$ɜ 5-FUɜ oxaliplatinɜ 
ilinotecanɜbevacizumab '&;ƛ8%$ĕļ×# 9ɝĦ*
Ù) in vivo )Šȅ$ EGCG _Xíǫƨǡșƻ)éí;Ĭ²8%;
ň6(ɝ/ɜíǫƨǏǤ$*'
3))ɜEGCG ( 5-FU 4 
oxaliplatin ;ƛĭx8%$ư}ºř;Ʃĸ8% in vitro $åÒ
9#
8 36,37ɝĕɜ íǫƨǏǤ(8 EGCG %ņð)Įƨµ%)ư}
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Ü 1ɝEGCG )éūĬ²ºř 
íǫƨǏǤŝ(û8 EGCG )éūĬ²ºř;ƚðǏǤĿ;Ƅò8 cell 
counting kit-8 ;ƛ
#Šȅɝ 
( A )  RKO ( EGCG ;ƀ¹ 24 ŋȾĕ(Ƅòɝ 
( B )  HCT116 ( EGCG ;ƀ¹ 24 ŋȾĕ(Ƅòɝ 
n = 8ɜGm`*ɜąá ± Ťƅā$ǻƸɝ 





Ü 2ɝEGCG )éūĬ²ºř 
íǫƨǏǤŝ(û8 EGCG )éūĬ²ºř; DNA Îĥ)ıŤ$	8 
BrdU ;ƛ
#Šȅɝ 
( A )  RKO ( EGCG ;ƀ¹ 24 ŋȾĕ(Ƅòɝ 
( B )  HCT116 ( EGCG ;ƀ¹ 24 ŋȾĕ(Ƅòɝ 
n = 8ɜGm`*ɜąá ± Ťƅā$ǻƸɝ 





Ü 3ɝEGCG )=eXsKMȍýºř 
EGCG )=eXsKMȍýºř;=eXsKMȧƽ$ƚ8łƎ½ DNA ;
Š¬8 TUNEL ŵ;ƛ
#ŠȅɝRKO ( EGCG ;ƀ¹ɜ4 ŋȾĕ
(Ƅòɝ 
( A ) EGCG 0 µMɜ( B ) EGCG 25 µMɜ( C ) EGCG 50 µMɜ( D ) EGCG 100 µM. 
ƳÂ*=eXsKM;ȖǏǤ;Ƹ#
8ɝ 





Ü 4ɝEGCG )=eXsKMȍýºř 
EGCG )=eXsKMȍýºř;=eXsKMȧƽ$ƚ8łƎ½ DNA ;
Š¬8 TUNEL ŵ;ƛ
#ŠȅɝHCT116 ( EGCG ;ƀ¹ɜ4 ŋ
Ⱦĕ(Ƅòɝ 
( A ) EGCG 0 µMɜ( B ) EGCG 25 µMɜ( C ) EGCG 50 µMɜ( D ) EGCG 100 µM. 
ƳÂ*=eXsKM;ȖǏǤ;Ƹ#
8ɝ 





Ü 5ɝEGCG KGZoȩ(x8Ēɋ 
íǫƨǏǤŝ( EGCG ;ƀ¹ɜ12 ŋȾĕ(Jrbo;ĵÈɝ





Ü 6ɝEGCG TqKrEZsOÉ÷(x8Ēɋ 
RKO ( EGCG ;ƀ¹ɜ2 ŋȾĕ(Jrbo;ĵÈɜn=oR?h 
RT-PCR $Šȅɝ 
( A ) VEGFR2ɜ( B ) EGFRɜ( C ) HER2ɜ( D ) c-Met. 
n = 4ɜGm`*ɜąá ± Ťƅā$ǻƸɝ 





Ü 7ɝEGCG )ǡșƻǪƦ(û8ºř 
RKO (58_XíǫƨǡșƻǪƦjWo;ǼɜEGCG )ĮǪƦºř;Š
ȅɝ 
( A ) control Ǜ ( Ā )ɜEGCG Ǜ ( Í ) )ǠƲ 
( B ) control Ǜ ( Ā )ɜEGCG Ǜ ( Í ) )ƤƘǑǘ 





Ü 8ɝEGCG )ǡșƻǪƦ(û8ºř 
ĺ¬ǡǮ$ŨăǡǮ(û8șƻǪƦ)Ɋƿ;ȄƄɝ  
n = 12ɜGm`*ɜąá  Ťƅā$ǻƸɝ 






( A ) control Ǜ ( Ā )ɜEGCG Ǜ ( Í ) ) TUNEL Śǲɝ 
( B ) control Ǜ ( Ā )ɜEGCG Ǜ ( Í ) ) anti-CD31 antibody (58¡ƣ
Śǲɝ 





Ü 10ɝEGCG f@M(Å.¶ƛ 
¶ƛ%#ɜȶê½ɜǸƁ ASTɜALT ;Šȅɝ 
( A ) ȶê½ɝ 
( B ) ǸƁ AST ɝ 
( C ) ǸƁ ALT ɝ 
n = 12ɜGm`*ɜąá  Ťƅā$ǻƸɝ 
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